A phase 2/3 multi-center study comparing Blinatumomab to standard of care in subjects with relapsed/refractory aggressive B-Cell non hodgkin lymphoma
A phase 2/3 multi-center study comparing Blinatumomab to standard of care in subjects with relapsed/refractory aggressive B-Cell non hodgkin lymphoma
Press Ctrl +⌘ + to increase font size.
Press Ctrl -⌘ - to decrease font size.
Press Ctrl 0⌘ 0 to reset font size.